1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.

CAMPATH-1 antibodies have a long and successful history in the treatment of leukaemia, autoimmune disease and transplant rejection. The first antibody to undergo "humanisation", CAMPATH-1H, permits treatment with limited patient anti-globulin response. It recognises the CD52 antigen which...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: James, L, Hale, G, Waldmann, H, Bloomer, A, Waldman, H
Materyal Türü: Journal article
Dil:English
Baskı/Yayın Bilgisi: 1999
_version_ 1826293714870337536
author James, L
Hale, G
Waldmann, H
Bloomer, A
Waldman, H
author_facet James, L
Hale, G
Waldmann, H
Bloomer, A
Waldman, H
author_sort James, L
collection OXFORD
description CAMPATH-1 antibodies have a long and successful history in the treatment of leukaemia, autoimmune disease and transplant rejection. The first antibody to undergo "humanisation", CAMPATH-1H, permits treatment with limited patient anti-globulin response. It recognises the CD52 antigen which is a small glycosylphosphatidylinositol(GPI)-anchored protein expressed on lymphocytes and mediates cell depletion. We present the 1.9 A structure of the CAMPATH-1H Fab complexed [corrected] with an analogue of the antigenic determinant of CD52. Analysis of the CAMPATH-1H binding site reveals that in contrast to most antibodies CDR L3 plays a dominant role in antigen binding. Furthermore CDR H3, which is essential for effective antigen recognition in most antibodies, participates in only two main-chain interactions in CAMPATH-1H. The CAMPATH-1H binding site is highly basic; ionic interaction with the enthanolamine phosphate of the CD52 GPI anchor has long been hypothesised to be important in antigen binding. The structure reveals a number of important specific ionic interactions, including Lys53H but not Lys52bH as had previously been suggested. Prolonged treatment with CAMPATH-1H can lead to patient anti-idiotype responses which may be exacerbated by the unusually high number of basic residues in the antibody. This suggests that a strategy where redundant basic residues are replaced with neutral counterparts may be effective in further reducing the immunogenicity of this versatile and widely used antibody.
first_indexed 2024-03-07T03:34:25Z
format Journal article
id oxford-uuid:bbcfd706-8cca-4df1-bba5-0b1a97ff0ce9
institution University of Oxford
language English
last_indexed 2024-03-07T03:34:25Z
publishDate 1999
record_format dspace
spelling oxford-uuid:bbcfd706-8cca-4df1-bba5-0b1a97ff0ce92022-03-27T05:19:43Z1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bbcfd706-8cca-4df1-bba5-0b1a97ff0ce9EnglishSymplectic Elements at Oxford1999James, LHale, GWaldmann, HBloomer, AWaldman, HCAMPATH-1 antibodies have a long and successful history in the treatment of leukaemia, autoimmune disease and transplant rejection. The first antibody to undergo "humanisation", CAMPATH-1H, permits treatment with limited patient anti-globulin response. It recognises the CD52 antigen which is a small glycosylphosphatidylinositol(GPI)-anchored protein expressed on lymphocytes and mediates cell depletion. We present the 1.9 A structure of the CAMPATH-1H Fab complexed [corrected] with an analogue of the antigenic determinant of CD52. Analysis of the CAMPATH-1H binding site reveals that in contrast to most antibodies CDR L3 plays a dominant role in antigen binding. Furthermore CDR H3, which is essential for effective antigen recognition in most antibodies, participates in only two main-chain interactions in CAMPATH-1H. The CAMPATH-1H binding site is highly basic; ionic interaction with the enthanolamine phosphate of the CD52 GPI anchor has long been hypothesised to be important in antigen binding. The structure reveals a number of important specific ionic interactions, including Lys53H but not Lys52bH as had previously been suggested. Prolonged treatment with CAMPATH-1H can lead to patient anti-idiotype responses which may be exacerbated by the unusually high number of basic residues in the antibody. This suggests that a strategy where redundant basic residues are replaced with neutral counterparts may be effective in further reducing the immunogenicity of this versatile and widely used antibody.
spellingShingle James, L
Hale, G
Waldmann, H
Bloomer, A
Waldman, H
1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title_full 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title_fullStr 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title_full_unstemmed 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title_short 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
title_sort 1 9 a structure of the therapeutic antibody campath 1h fab in complex with a synthetic peptide antigen
work_keys_str_mv AT jamesl 19astructureofthetherapeuticantibodycampath1hfabincomplexwithasyntheticpeptideantigen
AT haleg 19astructureofthetherapeuticantibodycampath1hfabincomplexwithasyntheticpeptideantigen
AT waldmannh 19astructureofthetherapeuticantibodycampath1hfabincomplexwithasyntheticpeptideantigen
AT bloomera 19astructureofthetherapeuticantibodycampath1hfabincomplexwithasyntheticpeptideantigen
AT waldmanh 19astructureofthetherapeuticantibodycampath1hfabincomplexwithasyntheticpeptideantigen